Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report.

Yuan, Fang; Liu, Nan; Yang, Ming-Zhen; Zhang, Xiao-Tian; Luo, Hong; Zhou, Hong

Yuan, Fang; Liu, Nan; Yang, Ming-Zhen; Zhang, Xiao-Tian; Luo, Hong; Zhou, Hong.

Afiliação

Yuan F; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400044, China.
Liu N; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400044, China.
Yang MZ; Department of Clinical Biochemistry, College of Medical Laboratory, Army Military Medical University, Chongqing 400038, China.
Zhang XT; Department of Medicine, BGI Genomics, Shenzhen 518083, Guangdong Province, China.
Luo H; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400044, China.
Zhou H; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400044, China. zhouhongcqch@126.com.

World J Clin Cases ; 10(11): 3461-3471, 2022 Apr 16.

Article em En | MEDLINE | ID: mdl-35611209

Palavras-chave

Circulating tumor DNA; Olaparib; Partner and localizer of BRCA2; Resistance mechanism; Reverse missense mutations; mCRPC

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: World J Clin Cases Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google